Desjardins Issues Negative Outlook for TSE:INO Earnings

Inovalis Real Estate Investment Trust (TSE:INO) – Analysts at Desjardins reduced their Q2 2025 earnings estimates for shares of Inovalis Real Estate Investment Trust in a research report issued to clients and investors on Wednesday, May 14th. Desjardins analyst A. Leon now forecasts that the company will post earnings of $0.01 per share for the quarter, down from their previous estimate of $0.02.

Inovalis Real Estate Investment Trust Price Performance

About Inovalis Real Estate Investment Trust

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.